News
News
May 06, 2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab-abbs or rituximab-pvvr plus chemotherapy in the United States.
News
May 06, 2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab-abbs…
News
May 04, 2021
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate…
News
April 20, 2021
Results from a recent study show the use of ovarian suppression was not associated with lower adherence to endocrine…
News
April 14, 2021
A recent real-world study compared HCRU and costs associated with first-line ibrutinib monotherapy vs bendamustine plus…
News
April 01, 2021
A recent study comparing brachytherapy, dose-escalated external beam radiotherapy, and stereotactic body radiation…
News
March 16, 2021
KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
News
March 12, 2021
Study results show adjuvant hormonal therapy adherence at 5 years are low among commercially insured patients with…
News
March 12, 2021
A methodology to identify high-value oncology care was developed using cost of care per patient per day in breast…
News
March 10, 2021
Testing a limited, clinically relevant subset of genes may optimize genetic testing for women diagnosed with ovarian or…
News
March 02, 2021
Study results show nivolumab monotherapy is effective for previously treated advanced NSCLC in real-world practice.